Cimg Inc's Business Segments

CIMG Inc., incorporated in Nevada and listed on Nasdaq since June 2020, initially operated in specialty coffee before expanding into the sales and distribution of healthy foods in Asia. The company utilizes AI computing technology to support user growth and product sales. In June 2024, CIMG sold its subsidiaries NuZee KOREA Ltd. and NuZee Investment Co., Ltd. to former CEO Masateru Higashida. Beginning in July 2024, CIMG restructured its digital marketing, distribution, and sales efforts to focus on Maca-enhanced food and beverages, securing exclusive Asian distribution rights for Kangduoyuan brand Maca products for three years. The Maca product line includes Maca Peptide Coffee, Maca-Noni (a plant-based energy drink without caffeine), Maca Wine, and Maca Purified Powder, all marketed through digital channels and online sales. The company also introduced the "Homology of Medicine and Food" series, featuring Huomao-branded health and wellness products based on traditional Chinese medicine and modern nutrition. CIMG sources, markets, and distributes health and wellness products with an emphasis on responsible and sustainable sourcing, selling through online platforms and retail partners. Since September 2025, the company has offered the "Computing Power Product" series, which includes AI-integrated GPUs designed for industry-specific data processing, primarily sold to business customers for integration into computing infrastructure. CIMG emphasizes quality, sustainability, and innovative packaging to serve diverse consumer groups.

The Company operates through two geographical segments: North America and China (P.R.C), jointly producing and selling products in these regions. For the year ended September 30, 2025, the Company reported four business segments: Homology of Medicine and Food Series, Computing Power Product Series, Maca Product Series, and others. The Chief Financial Officer, serving as the chief operating decision maker, reviews the Company's overall assets, operating results, and financial metrics to allocate resources and assess performance. Segment financial results for the year ended September 30, 2025, include net revenues of $6,349,252 for Homology of Medicine and Food Series, $3,804,691 for Computing Power Product Series, and $144,726 for Maca Product Series, totaling $10,298,669 before eliminations. The Company also reports costs, gross profit, operating expenses, allowance for credit loss, inventory impairment loss, loss from operations, fair value variation, loss on acquisition, goodwill impairment, other income, other expenses, and segment loss for these segments. For the year ended September 30, 2024, only the Maca Product Series was reported, with net revenues of $1,930,291. Related financial results included cost of revenue, gross profit, operating expenses, allowance for credit loss, inventory write-down, impairment loss on assets held for sale, loss from operations, fair value variation, loss from investment, other income, other expenses, and net interest expense.